These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 24990369)
1. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Miyagawa K; Emoto N Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369 [TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Chaumais MC; Guignabert C; Savale L; Jaïs X; Boucly A; Montani D; Simonneau G; Humbert M; Sitbon O Am J Cardiovasc Drugs; 2015 Feb; 15(1):13-26. PubMed ID: 25421754 [TBL] [Abstract][Full Text] [Related]
3. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613 [TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Rubin LJ Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806 [TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. de Raaf MA; Beekhuijzen M; Guignabert C; Vonk Noordegraaf A; Bogaard HJ Reprod Toxicol; 2015 Aug; 56():45-51. PubMed ID: 26111581 [TBL] [Abstract][Full Text] [Related]
6. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Opitz CF; Ewert R Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004 [TBL] [Abstract][Full Text] [Related]
8. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. Madonna R; Cocco N; De Caterina R Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170 [TBL] [Abstract][Full Text] [Related]
9. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Davie NJ; Schermuly RT; Weissmann N; Grimminger F; Ghofrani HA Eur J Clin Invest; 2009 Jun; 39 Suppl 2():38-49. PubMed ID: 19335746 [TBL] [Abstract][Full Text] [Related]
10. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Shao D; Park JE; Wort SJ Pharmacol Res; 2011 Jun; 63(6):504-11. PubMed ID: 21419223 [TBL] [Abstract][Full Text] [Related]
12. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension. Clozel M Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881 [TBL] [Abstract][Full Text] [Related]
13. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Raja SG Cardiovasc Ther; 2010 Oct; 28(5):e65-71. PubMed ID: 20406243 [TBL] [Abstract][Full Text] [Related]
14. [Endothelin receptor antagonists in pulmonary arterial hypertension]. Tokgöz HC; Can MM; Kaymaz C Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750 [TBL] [Abstract][Full Text] [Related]
17. Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis. Aubert JD; Juillerat-Jeanneret L J Med Chem; 2016 Sep; 59(18):8168-88. PubMed ID: 27266371 [TBL] [Abstract][Full Text] [Related]
18. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. Kim NH; Rubin LJ J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973 [TBL] [Abstract][Full Text] [Related]
19. Bosentan for the treatment of adult pulmonary hypertension. Dwyer N; Kilpatrick D Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507 [TBL] [Abstract][Full Text] [Related]
20. Macitentan for the treatment of pulmonary arterial hypertension. Kholdani CA; Fares WH; Trow TK Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]